home / stock / pypd / pypd short
Short Information | PolyPid Ltd. (NASDAQ:PYPD)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 17,471 |
Total Actual Volume | 125,294 |
Short Trends | |
---|---|
Cover Days | 17 |
Short Days | 1 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 874 |
Average Short Percentage | 17.67% |
Is there a PYPD Short Squeeze or Breakout about to happen?
See the PYPD Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-05-2024 | $3.99 | $4 | $4.11 | $3.99 | 3,323 | 15 | 0.45% |
07-03-2024 | $4 | $4 | $4.01 | $3.99 | 1,086 | 10 | 0.92% |
07-02-2024 | $3.98 | $4 | $4.02 | $3.98 | 2,235 | 1 | 0.04% |
07-01-2024 | $4.49 | $4.24 | $4.49 | $4.2 | 3,624 | 380 | 10.49% |
06-28-2024 | $4.25 | $4.3 | $4.4 | $4.125 | 15,640 | 1,624 | 10.38% |
06-26-2024 | $4.09 | $4.0786 | $4.09 | $4.0786 | 864 | 170 | 19.68% |
06-25-2024 | $4 | $3.8829 | $4 | $3.8829 | 829 | 29 | 3.5% |
06-24-2024 | $4 | $3.98 | $4 | $3.85 | 2,976 | 607 | 20.4% |
06-21-2024 | $4.26 | $4.26 | $4.26 | $4.26 | 506 | 36 | 7.11% |
06-20-2024 | $4.225 | $4 | $4.25 | $3.75 | 60,069 | 7,566 | 12.6% |
06-18-2024 | $4.2 | $4.11 | $4.4255 | $4.06 | 22,247 | 3,693 | 16.6% |
06-17-2024 | $4.36 | $4.185 | $4.37 | $4.1 | 4,185 | 1,178 | 28.15% |
06-14-2024 | $4.2403 | $4.24 | $4.2403 | $4.24 | 779 | 218 | 27.98% |
06-13-2024 | $4.3 | $4.3 | $4.4 | $4.3 | 1,607 | 678 | 42.19% |
06-12-2024 | $0 | $4.2377 | $0 | $0 | 16 | 1 | 6.25% |
06-11-2024 | $0 | $4.2377 | $0 | $0 | 117 | 13 | 11.11% |
06-07-2024 | $4.295 | $4.36 | $4.36 | $4.295 | 783 | 251 | 32.06% |
06-06-2024 | $0 | $4.15 | $0 | $0 | 52 | 31 | 59.62% |
06-05-2024 | $4.1 | $4.15 | $4.23 | $4.1 | 2,142 | 2 | 0.09% |
06-03-2024 | $4.5 | $4.15 | $4.5 | $4.1 | 2,214 | 968 | 43.72% |
News, Short Squeeze, Breakout and More Instantly...
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...